Pre-workout Supplement, Arrhythmias and Exercise Stress Test
Can a Pre-workout Supplement Cause Arrhythmias During Physical Exercise in Young Physically Active Individuals? A Randomized, Double-blind, Placebo-controlled Study
Pre-workout supplements are widely used by physically active individuals to enhance exercise performance. These products typically contain stimulant substances such as caffeine, beta-alanine, arginine, and tyrosine, which act on the cardiovascular and central nervous systems. Although their ergogenic effects are well established, their safety profile - particularly regarding cardiac arrhythmias during exercise - has not been thoroughly investigated.
This study aimed to evaluate whether the acute ingestion of a commercially available multi-ingredient pre-workout supplement (V-FORT® ULTRA, Vitafor, Brazil) could trigger cardiac arrhythmias during a treadmill exercise stress test in young, physically active adults. A randomized, double-blind, placebo-controlled crossover design was used. Participants underwent two exercise stress tests separated by 3 to 10 days: a familiarization test (Day 1) and an intervention test (Day 2), in which they received either the pre-workout supplement or a placebo beverage. Neither the participants nor the research team conducting the test were aware of the allocated intervention until after test completion.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Participants were recruited via social media and screened for eligibility using the International Physical Activity Questionnaire (IPAQ). Only individuals meeting the criteria for physical activity (≥150 minutes/week of moderate-intensity or ≥75 minutes/week of vigorous-intensity exercise) and with prior experience using pre-workout supplements were enrolled.
On Day 1, all participants underwent a familiarization treadmill exercise stress test. Those presenting cardiac arrhythmias at baseline were excluded from the study.
On Day 2 (3 to 10 days later), participants were randomized in a 1:1 ratio to receive either the active supplement (V-FORT® ULTRA: 200 mg caffeine, 2,000 mg beta-alanine, 1,000 mg arginine, 600 mg tyrosine, 300 mg phenylalanine, 415 mg carnitine, vitamins and minerals; 8 kcal per 8 g sachet) or a placebo (Tang® powdered juice: carbohydrates, sodium, vitamin C, and vitamin D; no stimulant substances). The beverage was prepared by the study coordinator in a separate room and consumed by the participant up to 3 hours before the exercise stress test. Both tests were performed at the same time of day for each participant.
The primary outcome was the occurrence of cardiac arrhythmias during the exercise stress test and the 6-minute post-exercise recovery phase, assessed by continuous 12-lead ECG. Secondary outcomes included adverse effects (tachycardia, paraesthesia) and exercise stress test duration.
Statistical analysis included descriptive statistics, normality testing (Shapiro-Wilk), paired comparisons (paired t-test or Wilcoxon signed-rank test for continuous variables; McNemar test for categorical variables), and logistic regression for confounder adjustment. IBM SPSS software was used for all analyses.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
São Paulo
-
São Paulo, São Paulo, Brasile, 05021-010
- Pro-Coracao
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Age 18 to 30 years Both sexes Physically active, defined as engaging in at least 150 minutes of moderate-intensity physical activity or 75 minutes of vigorous-intensity physical activity per week, assessed by the International Physical Activity Questionnaire (IPAQ) Prior experience with pre-workout supplements (at least one previous use of any stimulant-based pre-workout supplement) No cardiac arrhythmias identified during the familiarization exercise stress test (Day 1)
Exclusion Criteria:
Presence of cardiac arrhythmias identified during the familiarization exercise stress test (Day 1) Physical inactivity (below the minimum physical activity thresholds on IPAQ) No prior use of any pre-workout or stimulant supplement Use of medications that may interfere with cardiovascular responses to exercise or supplementation Presence of known cardiovascular, metabolic, or musculoskeletal conditions that contraindicate exercise testing Orthopaedic limitations precluding treadmill exercise
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Pre-Workout Supplement
Participants received a single dose of V-FORT® ULTRA (Vitafor, Brazil), a multi-ingredient pre-workout supplement containing 200 mg caffeine, 2,000 mg beta-alanine, 1,000 mg arginine, 600 mg tyrosine, 300 mg phenylalanine, 415 mg carnitine, 1.9 g carbohydrate, vitamins (C, E, B6, B12) and minerals (sodium, magnesium, zinc); 8 kcal per 8 g sachet. The beverage was consumed up to 3 hours before the treadmill exercise stress test. |
Single dose of containing 200 mg caffeine, 2,000 mg beta-alanine, 1,000 mg arginine, 600 mg tyrosine, 300 mg phenylalanine, 415 mg carnitine, 1.9 g carbohydrate, vitamins (C, E, B6, B12) and minerals (sodium, magnesium, zinc); 8 kcal per 8 g sachet. Consumed up to 3 hours before the treadmill exercise stress test. |
|
Comparatore placebo: Placebo
Participants received a single dose of Tang® powdered juice (placebo), containing 2.6 g carbohydrate, 2.4 g sugars, 22 mg sodium, 1.1 mg zinc, 23 mg vitamin C, and 2.5 mcg vitamin D, with no stimulant substances. The beverage was prepared to be visually and organoleptically indistinguishable from the active supplement and was consumed up to 3 hours before the treadmill exercise stress test. |
Juice |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Occurrence of Cardiac Arrhythmias During the Exercise Stress Test
Lasso di tempo: During the treadmill exercise stress test and throughout the 6-minute post-exercise recovery phase (approximately 30 to 60 minutes per session, on Day 2)
|
Presence or absence of cardiac arrhythmias identified on continuous 12-lead ECG during the treadmill exercise stress test and the 6-minute post-exercise recovery phase, compared between the pre-workout supplement and placebo conditions. |
During the treadmill exercise stress test and throughout the 6-minute post-exercise recovery phase (approximately 30 to 60 minutes per session, on Day 2)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Haemodynamic Responses During the Exercise Stress Test
Lasso di tempo: At rest, during each stage of the treadmill exercise stress test, at peak effort, and during the 6-minute post-exercise recovery phase on Day 2
|
Blood pressure (systolic and diastolic) and heart rate measured at rest, at the end of each exercise stage, at peak effort, and during the post-exercise recovery phase (minutes 1, 2, 4, and 6), compared between the pre-workout supplement and placebo conditions. |
At rest, during each stage of the treadmill exercise stress test, at peak effort, and during the 6-minute post-exercise recovery phase on Day 2
|
|
Exercise Stress Test Duration
Lasso di tempo: Day 1 (familiarization test) and Day 2 (intervention test), separated by 3 to 10 days
|
Total duration of the treadmill exercise stress test in minutes, compared between the pre-workout supplement and placebo conditions (Day 2), and between the familiarization test (Day 1) and the intervention test (Day 2) within the same participant. |
Day 1 (familiarization test) and Day 2 (intervention test), separated by 3 to 10 days
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 8.071.338
- 92811525.4.0000.0068 (Altro identificatore: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .